Hangzhou and Shaoxing, China, June 24, 2019 --Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that the company will attend Goldman Sachs China Healthcare Corporate Day 2019 on 26 June 2019 in Hong Kong.
Ascletis is an innovative R&D driven biotech with two commercial products and listed on Hong Kong Stock Exchange (Ascletis, 1672.HK). Ascletis’ mission is to address unmet medical needs in three therapeutic areas: viral, cancer and fatty liver diseases. Led by a management team with deep expertise and a proven track record, Ascletis has developed a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Ascletis is now commercializing two drugs, Ganovo? (danoprevir), the first direct-acting anti-viral agent for hepatitis C developed domestically for China, and Pegasys? (peginterferon alfa-2a), a well-established pegylated interferon for hepatitis B & C partnered with Roche. Ascletis’ R&D pipeline consists of antibody-based immunotherapy, first/best-in-class small molecules and siRNA at various clinical development stages. For more information, please visit www.ascletis.com.
Chenlin Li, +86-159-6815-8530